1. Introduction
===============

Neuroblastoma is a common abdominal malignancy in children with relatively poor prognosis compared with other childhood tumors. Choice of treatment procedure is made according to the risk stratification based on clinical manifestations and the pathological type. In the international neuroblastoma staging system (INSS) commonly used in the clinic,^\[[@R1]\]^ any primary tumor with dissemination to distant organs is defined as stage IV that requires chemotherapy before and after radical surgery. Common migration sites include the lymph nodes, bone marrow, bone, liver, and skin. Metastasis of neuroblastoma to the lung is rare, with a reported occurrence rate of 3% to 4%,^\[[@R2]\]^ and diffused dissemination to the lung is extremely rare.

The histological manifestation of neuroblastoma is highly heterogeneous. Its mutational dynamics is to be investigated for the practice of precision medicine. Up to now, only a few studies using next-generation sequencing (NGS) to analyze the genetic background of neuroblastoma have been reported.^\[[@R3]--[@R9]\]^ However, the paradigm of classical driver genes including *MYC*, *RAS*, and *ALK* has not been shifted, and not much progress has been made in discovery of applicable therapeutic targets.

The DNA mismatch repair (MMR) system is a mechanism for genome maintenance. The system is composed of proteins that can recognize and degrade one strand of DNA and use the complementary strand as a repair template to eliminate the mismatch.^\[[@R10]\]^ The MMR system in human is composed of 6 proteins: hMSH2, hMSH3, hMSH6, hMLH1, hMLH3, and hPMS1. Defect of the MMR system substantially elevates spontaneous mutation rates. In pediatrics, constitutional MMR deficiency (CMMRD) syndrome is resulted from biallelic germline loss-of-function mutations in one of the MMR genes. Individuals with CMMRD have a high risk to develop a broad spectrum of malignancies, including high-grade glioma, acute myeloid leukemia, or rhabdomyosarcoma.^\[[@R11]\]^ MMR deficiency was found first to contribute to colorectal cancer,^\[[@R12]\]^ later in many other types of cancers, and this pathological condition has been named as Lynch syndrome that is replacing the definition of CMMRD.^\[[@R13]\]^ In pediatric neuroblastoma, analysis of MMR proteins expression levels has been reported.^\[[@R14]\]^ In cultured neuroblastoma cells, MMR deficiency contributes to the malignant behaviors such as colony formation.^\[[@R15]\]^ In this case report, a highly malignant neuroblastoma with lung metastasis and multiple drug resistance (MDR) is reported. The genetics background was analyzed using NGS combined with traditional methods.

2. Materials and methods
========================

2.1. Sample collection
----------------------

This research was approved by the institutional ethical committee in 2014 and was done in accordance with the Helsinki Declaration of 1975. Signed informed consent forms were obtained from the patient\'s guardian. Tissue samples were taken after surgery. Neuroblastoma with poor differentiation was diagnosed by postsurgical pathological examinations. Whole blood with anticoagulant was also collected.

2.2. Whole exome sequencing
---------------------------

NGS was performed by Novogene, Beijing, China. Total DNA was extracted from the tissue and the blood. After building the DNA library, target exome sequences were captured by liquid-phase chips (Agilent) and were sequenced by NGS (Hiseq 2000; Illumina). Somatic SNV was analyzed by muTect (muTect-1.1.4.jar) and by COSMIC plus DBSNP online databases.

2.3. Pathological analysis
--------------------------

Tissues were fixed in 4% paraformaldehyde, embedded in paraffin and cut into 4 μm sections, then subjected to hematoxylin and eosin (HE) staining. Immunohistochemistry (IHC) analysis was performed by primary antibodies against hMSH2 and hMLH1 (Protein Tech) and with a biotinylated peroxidase-conjugated streptavidin system (Bio-Genex Laboratories). IHC of SYN, CD56, vimentin, CD99, Wilms' tumor 1 (WT1), epidermal growth factor receptor (EMA), and desmin (primary antibodies from Dako, Denmark) were also performed. All specimens were scanned by 3DHistech (Pannoramic, Hungary) with companion software.

2.4. Fluorescence in situ hybridization (FISH)
----------------------------------------------

Amplification of *Myc* was detected by commercial kit (Vysis, Abbott) using fluorescent probe against the *c-Myc* and *n-Myc* genes in sectioned paraffin-embedded tissue. Based on the guidelines of European neuroblastoma quality assessment (ENQUA),^\[[@R16]\]^ over 100 cells were counted. As the diagnostic criteria, samples with \<5% cells with \>4 probes bound to the chromosomes were considered negative.

3. Case report
==============

3.1. Clinical data and treatment procedure
------------------------------------------

The patient was a boy aged 2 years and 8 months when first admitted to the hospital due to palpable left-side abdominal mass. Needle biopsy and pathological examinations diagnosed the patient as neuroblastoma with poor differentiation. No migration to the bone marrow was detected. Computed tomography (CT) revealed multiple migration loci in the lung and pleural fluid (Fig. [1](#F1){ref-type="fig"}A), but no migration to the liver or to the bone. The patient received chemotherapy for 4 months by combination of vindesine+ifosfamide+etoposide and vindesine+tsprubicine+carboplatin, topotecan, and gemcitabine were also used. Then radical section of the tumor together with the left kidney and the left adrenal gland was performed 5 months after diagnosis. Pathological examinations confirmed neuroblastoma with poor differentiation and massive necrosis. A later CT showed that after first session of chemotherapy, both the number and the size of the high-density loci in the lung were reduced (Fig. [1](#F1){ref-type="fig"}B). The patient received several postsurgical chemotherapy protocols similar with the previous. He was always developing severe bone marrow suppression upon chemotherapy with low white blood cell and platelet counts, and severe respiratory inflammation. Follow-up CT scans found no relapse of the original tumor in the adrenal gland, but multiple metastatic loci in both lungs, with new loci developed after surgery (Fig. [1](#F1){ref-type="fig"}C). No metastasis in other organs was detected. The patient died 22 months after diagnosis, 17 months after surgery. The timeline of the reported case from initial diagnosis to death is summarized in Table [1](#T1){ref-type="table"}.

![CT scans of the metastatic tumors in the lung. (A) Image of a representative window at primary diagnosis. (B) Image of the same window after chemotherapy and surgery. (C) Image of the same window in the follow-up examinations after tumor relapses. Arrows indicate the loci of the metastatic tumors.](medi-96-e8845-g001){#F1}

###### 

The timeline of the reported case from initial diagnosis to death.

![](medi-96-e8845-g002)

3.2. Pathology and FISH
-----------------------

In the tissue from needle biopsy of the mass from left kidney by HE staining (Fig. [2](#F2){ref-type="fig"}A), necrosis was commonly seen. Clusters of tumor cells with poor differentiation and with round nuclei could be observed; no anaplastic cells were observed; spindle-like fibers could be observed. The postsurgery specimen was the sectioned left kidney, left adrenal gland together with the tumor. The tumor was located above the kidney, with a size of 7 × 6.5 × 5 cm and massive necrotic area of 5.5 × 5 cm. The tumor had invaded the envelope of the kidney, but not into the renal pelvis and the ureter. Blood congestion, edema, and partial hyaloid degeneration were observed in the fat and fibrous tissues surrounding the tumor mass. Postsurgical pathological examinations revealed similar cellular morphology with significant necrosis and poor differentiation (Fig. [2](#F2){ref-type="fig"}A).

![Expression of *Myc* gene and MMR proteins in the tumor tissues. (A) HE staining of tumor tissues obtained by needle biopsy and by surgery (200×). (B) IHC of CD56 and Syn, and FISH analysis of *c-Myc* and *n-Myc* of tumor tissue sectioned after chemotherapy (400×). (C) IHC of hMLH1 and hMSH2 in this case and a control neuroblastoma case without identified MMR mutation (200×).](medi-96-e8845-g003){#F2}

IHC showed positive staining for SYN, CD56, vimentin, with Ki-67 \>30%, and negative staining for CD99, WT1, EMA, and desmin. FISH showed negative for both *c-Myc* and *n-Myc* amplification (Fig. [2](#F2){ref-type="fig"}B).

IHC revealed positive staining of MMR markers, hMSH2 and hMLH1, in the nucleus region in normal kidney in this case. This was the same result as obtained from tissues of another neuroblastoma case without identified mutation (Fig. [2](#F2){ref-type="fig"}C), as well as other control tissues (data not shown). No significant decrease in hMSH2 and hMLH1 levels was found in this case.

3.3. Somatic mutations revealed by NGS
--------------------------------------

A total of 9666 somatic SNVs from 5148 genes were detected. The number of somatic SNV detected in different regions of the genes is shown in Table [2](#T2){ref-type="table"}. Among the 3111 mutations in the exon-coding CDS region, 1469 mutations of missense, stoploss, and stopgain mutations that would cause change of amino acid sequences or the length of proteins. A total of 1171 genes were affected, and 1008 (85.9%) were mapped to 1386 distinct proteins in ConsensusPathDB. In pathway analysis, a total of 608 genes (53.4%) were present in at least one of 19 pathways identified. The 19 pathways enriched in mutated genes/proteins are listed in Table [3](#T3){ref-type="table"}. NGS also revelaed 55 copy number variations (CNVs) and 140 insertion--deletion variations (INDELs) in this case.

###### 

The number of somatic SNV detected in different regions of the genome.
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###### 

The pathways enriched in mutated genes/proteins analyzed by ConsensusPathDB.
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Table [4](#T4){ref-type="table"} contains the druggable gene targets predicted by detected mutations. Potentially effective drugs in targeted therapy were anti-EGFR antibodies, and anthracyclines/related substances such as adriamycin. It was also suggested that the tumor cells could be sensitive to HMG-CoA and ACEI, which are nonrelevant to tumor chemotherapy.

###### 

Therapeutic targets predicted by analysis of mutated genes.
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Mutation of *MSH2* is shown in Table [5](#T5){ref-type="table"}. A heterozygous mutation C23T from exon 1 of this gene was identified, leading to a mutation of T8 M in the protein level. The mutation rate was 6.3% (2/48) in this sample.

###### 

Characteristics of *MSH2* mutations identified.
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4. Discussion
=============

Here we report a case of highly malignant neuroblastoma with diffused metastatic loci in the lung. Pathological examination revealed typical undifferentiated neuroblastoma cells. MDR of the metastatic tumors, as well as bone marrow suppression after chemotherapy, has made it an obstinate case in pediatric oncology. To study the genetic background of the tumor and to search for drug targets, NGS was performed to analyze the somatic mutations in the exon region. A substantially increased number of somatic mutations, especially SNVs, were identified. However, the underlying mechanism of the malignacy remained undefined. It is known that severe neuroblastoma cases are frequently associated with amplication of the *Myc* gene. Other driver genes including *p53* and *ALK* are also frequently involved. However, in this case, even with a powerful tool of NGS, no SNV, INDEL, or CNV mutations of the above key driver genes have been found. On the other hand, a total of 9666 somatic SNVs from 5148 genes were detected, and pathway analysis implies that many cellular functions could be impaired, such as cellular matrix and immune response. The relationship between the many somatic SNVs and the dysregulation of cellular pathways remains unclear.

Defects in the DNA repair system can cause genome instability and increased mutation rate. One important mechanism is the MMR system. Germ-line mutations of MMR-related genes lead to the Lynch syndrome, previously called HNPCC. However, in this case, the genes of all MMR components do not carry mutations except for *MSH2* that carried a heterozygous missense SNV mutation. Based on a recent study of functional screening to identify pathogenic *MSH2* mutation, the T8 M mutation was proved to be nonpathogenic.^\[[@R17]\]^ Further IHC analysis did not produce evidence of MMR deficiency in the protein level.

Although NGS can be a powerful tool to guide personalized precision treatment, at current stage, even without consideration of the relatively high cost, its application in the clinic still has its limits. First, the procedure to obtain representative tumor tissue has intrinsic difficulty because tumors are highly heterogeneous. Sites like lung metastatic loci are not readily accessible for biopsy. In this case, some lung migration sites were responsive to treatment, whereas others manifested different response. Theoretically, it would be informative to compare the genetics of different loci, but is difficult to practice. Second, the number of druggable target molecules is limited. In this case, drug target analysis based on NGS data suggested that the tumor might be sensitive to anti-EGFR antibodies and adriamycin. Although anti-EGFR antibodies are potentially effective, they are not readily available in the clinic of pediatric oncology in China and in many developing countries. Furthermore, there are many potential targets without effective compounds. It is somewhat perplexing that in our clinical protocol, vindesine, an analogue of adriamycin predicted as an effective treatment option, did not result in improved clinical outcome, suggesting the current data interpretation tools could be inadequate. The last but not the least, our knowledge toward the genetics background of neuroblastoma is still very limited. The case reported is an example of pronounced somatic mutations but without identified driver gene and therapeutic target. Deeper understanding of the oncogenetics, as well as optimization of analytical tools, must be achieved before NGS data can provide more diagnostic and therapeutic insight in the clinic.
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Abbreviations: ACEI = angiotension-converting enzyme inhibitors, ALK = anaplastic lymphoma kinase, CDS = coding sequence, CMMRD = constitutional DNA mismatch repair deficiency, CNV = copy number variation, CT = computed tomography, EGFR = epidermal growth factor receptor, EMA = epithelial membrane antigen, ENQUA = European neuroblastoma quality assessment, FISH = fluorescence in situ hybridization, HE = hematoxylin and eosin, hMLH = human MutL homologs, hMSH = human MutS homologs, IHC = immunohistochemistry, INDEL = insertion--deletion variation, INSS = neuroblastoma staging system, MDR = multiple drug resistance, MMR = DNA mismatch repair, ncRNA = noncoding RNA, NGS = next generation sequencing, SNP = single-nucleotide polymorphism, SNV = single-nucleotide variant, SYN = synapsin, TSS = transcription start site, TTS = transcription termination site, UTR = untranslated region, WT1 = Wilms' tumor 1.
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